162 related articles for article (PubMed ID: 399376)
1. Human-derived immune globulins for the treatment of botulism.
Metzger JF; Lewis GE
Rev Infect Dis; 1979; 1(4):689-92. PubMed ID: 399376
[TBL] [Abstract][Full Text] [Related]
2. Question 1: In infant botulism, is equine-derived botulinum antitoxin (EqBA) an effective alternative therapy to human-derived botulinum immune globulin (BIG)?
Moneim J
Arch Dis Child; 2018 Sep; 103(9):907-909. PubMed ID: 30007943
[No Abstract] [Full Text] [Related]
3. Botulinum antitoxins and antibacterial IgM and IgG antibodies in sera of persons immunized with botulinum polytoxoid combined with cholera vaccine. I. Response to botulinum toxoid.
Galazka A; Rymkiewicz D; Aleksandrowicz J
Arch Immunol Ther Exp (Warsz); 1976; 24(5):631-9. PubMed ID: 793566
[TBL] [Abstract][Full Text] [Related]
4. Botulism immune plasma (human).
Lewis GE; Metzger JF
Lancet; 1978 Sep; 2(8090):634-5. PubMed ID: 80561
[No Abstract] [Full Text] [Related]
5. Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt.
Hibbs RG; Weber JT; Corwin A; Allos BM; Abd el Rehim MS; Sharkawy SE; Sarn JE; McKee KT
Clin Infect Dis; 1996 Aug; 23(2):337-40. PubMed ID: 8842274
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment for botulism.
Chalk C; Benstead TJ; Keezer M
Cochrane Database Syst Rev; 2011 Mar; (3):CD008123. PubMed ID: 21412916
[TBL] [Abstract][Full Text] [Related]
7. Botulism.
Sobel J
Clin Infect Dis; 2005 Oct; 41(8):1167-73. PubMed ID: 16163636
[TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.
Yu YZ; Zhang SM; Ma Y; Zhu HQ; Wang WB; Du Y; Zhou XW; Wang RL; Wang S; Yu WY; Huang PT; Sun ZW
Clin Immunol; 2010 Nov; 137(2):271-80. PubMed ID: 20696619
[TBL] [Abstract][Full Text] [Related]
9. Infant botulism and indications for administration of botulism immune globulin.
Pifko E; Price A; Sterner S
Pediatr Emerg Care; 2014 Feb; 30(2):120-4; quiz 125-7. PubMed ID: 24488164
[TBL] [Abstract][Full Text] [Related]
10. [Specific antitoxic therapy of botulism].
Nikiforov VN; Nikiforov VV; Glukhikh OA; Tashpulatov ShA
Sov Med; 1985; (10):46-50. PubMed ID: 3909448
[No Abstract] [Full Text] [Related]
11. [Botulism: prevention, clinical diagnostics, therapy and possible threat].
Gutzwiller FS; Steffen R; Mathys P; Walser S; Schmid H; Mütsch M
Dtsch Med Wochenschr; 2008 Apr; 133(16):840-5. PubMed ID: 18398794
[TBL] [Abstract][Full Text] [Related]
12. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E.
Hatheway CH; Snyder JD; Seals JE; Edell TA; Lewis GE
J Infect Dis; 1984 Sep; 150(3):407-12. PubMed ID: 6481185
[TBL] [Abstract][Full Text] [Related]
13. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
Khouri JM; Motter RN; Arnon SS
Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762
[TBL] [Abstract][Full Text] [Related]
15. Management of an outbreak of botulism with benign clinical presentation.
Equiza J; Campo-Caballero D; Rodríguez-Antigüedad J; Iruzubieta P; Vinagre-Aragón A; Echeverria J; Imaz N; Alberdi T; López de Munain A; Urtasun M; Espinal JB
J Clin Neurosci; 2021 Jun; 88():159-162. PubMed ID: 33992177
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques.
Kodihalli S; Emanuel A; Takla T; Hua Y; Hobbs C; LeClaire R; O'Donnell DC
PLoS One; 2017; 12(11):e0186892. PubMed ID: 29166654
[TBL] [Abstract][Full Text] [Related]
17. Infant botulism.
Arnon SS
Annu Rev Med; 1980; 31():541-60. PubMed ID: 6772092
[No Abstract] [Full Text] [Related]
18. Development of vaccines for prevention of botulism.
Byrne MP; Smith LA
Biochimie; 2000; 82(9-10):955-66. PubMed ID: 11086225
[TBL] [Abstract][Full Text] [Related]
19. Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review.
Schussler E; Sobel J; Hsu J; Yu P; Meaney-Delman D; Grammer LC; Nowak-Wegrzyn A
Clin Infect Dis; 2017 Dec; 66(suppl_1):S65-S72. PubMed ID: 29293931
[TBL] [Abstract][Full Text] [Related]
20. [Human anti-botulin immunoglobulin in botulism].
Nikiforov VN; Nikiforov VV; Tashpulatov ShA; Al'bitskaia NB; Kuznetsova VI
Sov Med; 1985; (2):63-6. PubMed ID: 3992329
[No Abstract] [Full Text] [Related]
[Next] [New Search]
